|1.||LaRochelle, William J: 3 articles (06/2008 - 02/2006)|
|2.||Jeffers, Michael: 2 articles (06/2008 - 02/2006)|
|3.||Senter, Peter D: 2 articles (08/2007 - 02/2006)|
|4.||Pollack, Vincent A: 2 articles (08/2007 - 02/2006)|
|5.||Lichenstein, Henri S: 2 articles (08/2007 - 02/2006)|
|6.||Shenoy, Suresh G: 2 articles (08/2007 - 02/2006)|
|7.||Tse, Kam Fai: 2 articles (08/2007 - 02/2006)|
|8.||MacDougall, John R: 2 articles (08/2007 - 02/2006)|
|9.||Li, J: 1 article (01/2012)|
|10.||Liu, F Y: 1 article (01/2012)|
08/01/2007 - "Short-term anti-tumor effects and long-term effects (complete regression) were observed with CR011-vcMMAE, but not with the reference agents. "
08/01/2007 - "CR011-vcMMAE could be delivered by either a single bolus dose or by intermittent dosing (i.e., every 1, 2, 4, 8, or 16 days) with no discernible differences in the proportion of tumor-free survivors, indicating a lack of schedule dependency. "
06/01/2008 - "Previous studies have shown that CR011-vcMMAE induces the apoptosis of GPNMB-expressing tumor cells in vitro and tumor regression in xenograft models. "
01/01/2012 - "Gpnmb/OA represents an attractive target in cancer immunotherapy and CR011-vcMMAE holds promise as a reagent in targeted therapy for Gpnmb/OA-expressing malignancies."
08/01/2007 - "Our prior study characterized a fully human antibody to GPNMB covalently linked to monomethylauristatin E, CR011-vcMMAE, and further demonstrated cell surface staining of melanoma lines susceptible to the immunoconjugate's cytotoxicity (Clin Cancer Res 2005; 12(4): 1373-1382). "
|2.||Melanoma (Melanoma, Malignant)
06/01/2008 - "These experiments lead to the identification of three distinct groups of compounds that increased GPNMB, some of which were shown to enhance the sensitivity of melanoma cells to CR011-vcMMAE. "
06/01/2008 - "Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate."
08/01/2007 - "These results suggest that CR011-vcMMAE may provide therapeutic benefit in malignant melanoma."
02/15/2006 - "However, when linked to the cytotoxic agent monomethylauristatin E (MMAE) to generate the CR011-vcMMAE antibody-drug conjugate, this reagent now potently and specifically inhibited the growth of GPNMB-positive melanoma cells in vitro. "
02/15/2006 - "In a melanoma xenograft model, CR011-vcMMAE induced significant dose-proportional antitumor effects, including complete regressions, at doses as low as 1.25 mg/kg. These preclinical results support the continued evaluation of CR011-vcMMAE for the treatment of melanoma."
|1.||Heterologous Transplantation (Xenotransplantation)